Global Ribonucleic Acid (RNA) Interference Market, By Type (dsRNA, siRNA, miRNA), Application (Drug Discovery and Development, Therapeutics, Other Applications) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the ribonucleic acid (RNA) interference market has been growing at a high pace and is expected to continue growing within the forecasted period. The market has been greatly affected by the recent outbreak of the COVID-19, which has been showing a positive impact for the market. The growing demand for RNAi drug delivery technologies due to the increasing occurrences of genetic disorders which are prevalent across the globe.
Data Bridge Market Research analyses that the ribonucleic acid (RNA) interference market is expected to grow at a CAGR of 19.35% during the forecast period of 2022 to 2029. The “therapeutics” segment accounts for the largest application segment in the ribonucleic acid (RNA) interference market within the forecasted period.
Market Definition
The ribonucleic acid interference (also known by different names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling) is one of the most important methods of analyzing gene functions in eukaryotes. It is a biological process in which RNA molecules neutralize the targeted mRNA molecules, inhibiting gene expression or translation.
Ribonucleic Acid (RNA) Interference Market Dynamics
Drivers
-
Increasing Occurrences of Genetic Disorders
The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe is the most significant factor driving the growth for this market. In addition to this, the rising geriatric population, which is more susceptible to such ailments is also projected to boost the overall growth of the market.
Moreover, the favorable reimbursement policies of the government is also expected to fuel market growth. The increasing the application of RNAi in molecular diagnosis and its viability as a therapeutic technique is also projected to cushion the growth of the market. Moreover, its usage for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions also cushions the market’s growth within the forecasted period.
Opportunities
Furthermore, the various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors by the market players extend profitable opportunities to the market players in the forecast period of 2022 to 2029. Moreover, the extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics will further expand the ribonucleic acid (RNA) interference market's growth rate in the future.
Restraints/Challenges
On the other hand, the requirement of FDA approval for a new drug along with less provision of healthcare facilities in developing regions is expected to obstruct market growth. Also, the decline in the number of innovative drugs and therapeutics manufactured are projected to challenge the ribonucleic acid (RNA) interference market in the forecast period of 2022-2029.
This ribonucleic acid (RNA) interference market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the ribonucleic acid (RNA) interference market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Ribonucleic Acid (RNA) Interference Market
The healthcare industry has been heavily impacted by the COVID-19. Ribonucleic acid (RNA) interference market however, was positively affected by the market as the sudden emergence of the pandemic offered crucial growth opportunities for the market. Moreover, the growing investments in healthcare to improve facilities have prompted the use of advanced medical devices in hospitals.
In conclusion, the coronavirus disease (COVID-19) resulted in significant increase in the demand for RNAi drug delivery technologies, and the increased demand for the RNAi drug delivery technologies had a positive impact on the ribonucleic acid (RNA) interference market.
Global Ribonucleic Acid (RNA) Interference Market Scope
The ribonucleic acid (RNA) interference market is segmented on the basis of type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- dsRNA
- siRNA
- miRNA
On the basis of type, the ribonucleic acid (RNA) interference market is segmented into dsRNA, siRNA and miRNA.
Application
- Drug Discovery and Development
- Therapeutics
- Other Applications
On the basis of application, the ribonucleic acid (RNA) interference market is segmented into drug discovery and development, therapeutics, other applications. Therapeutics have been further segmented into oncology, ocular disorders, respiratory disorders, hepatitis B and C, autoimmune hepatitis, neurological disorders and other therapeutics.
Ribonucleic Acid (RNA) Interference Market Regional Analysis/Insights
The ribonucleic acid (RNA) interference market is analyzed and market size insights and trends are provided by country, type and application as referenced above.
The countries covered in the ribonucleic acid (RNA) interference market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the ribonucleic acid (RNA) interference market because of the high prevalence of research institute and companies, increasing investment for the development of technical and medical advances, increasing occurrence of cancer and liver disorders and growing geriatric population will boost the growth of the market in this region. Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 owing to the increased investment by major companies in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Pipeline Analysis
The pipeline analysis of ribonucleic acid (RNA) interference drugs includes pipeline therapy such as DCR-A1AT for the treatment of alpha-1 antitrypsin (A1AT) deficiency-associated liver disease. Dicerna Pharmaceuticals has applied to the Swedish Medical Products Agency for a Clinical Trial Authorization (CTA) (MPA). The goal is to get approval to start a first-in-human Phase I/II clinical trial of DCR-A1AT for the treatment of A1AT deficiency-related liver disease. Dicerna focuses on RNA interference, also known as RNAi.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The ribonucleic acid (RNA) interference market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for ribonucleic acid (RNA) interference market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the ribonucleic acid (RNA) interference market. The data is available for historic period 2010-2020.
Competitive Landscape and Ribonucleic Acid (RNA) Interference Market Share Analysis
The ribonucleic acid (RNA) interference market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to ribonucleic acid (RNA) interference market.
Some of the major players operating in the ribonucleic acid (RNA) interference market are Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Merck KGaA, QIAGEN, Thermo Fisher Scientific, Quark Software Inc., Silence Therapeutics, Phio Pharmaceuticals Corp, and Benitec Biopharma among others.
SKU-